13th Annual Oncology Grand Rounds

A Complimentary NCPD Live Webinar Series
Held During the 46th Annual ONS Congress

Multiple Myeloma

Tuesday, April 27, 2021
8:30 AM – 10:00 AM ET

Medical Oncologists

Shaji K Kumar, MD
Sagar Lonial, MD
Paul G Richardson, MD

Oncology Nurse Practitioners

Charise Gleason, MSN, NP-C, AOCNP
Patricia Mangan, RN, MSN, CRNP, APN, BC
Tiffany A Richards, PhD, ANP-BC, AOCNP

Moderator

Neil Love, MD

RTP RESEARCH TO PRACTICE

Medical Oncologists

Shaji K Kumar, MD
Mark and Judy Mullins Professor of
Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Sagar Lonial, MD
Chair and Professor
Department of Hematology and
Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Paul G Richardson, MD
Clinical Program Leader and Director of
Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
RJ Corman Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Oncology Nurse Practitioners

Charise Gleason, MSN, NP-C, AOCNP
Advanced Practice Provider Chief
Winship Cancer Institute of Emory University
Adjunct Faculty, Nell Hodgson Woodruff
School of Nursing
Atlanta, Georgia

Patricia Mangan, RN, MSN, CRNP, APN, BC
Nurse Lead, Hematologic Malignancies and
Stem Cell Transplant Programs
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Tiffany A Richards, PhD, ANP-BC, AOCNP
Nurse Practitioner
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

RTP
RESEARCH
TO PRACTICE

Commercial Support

This activity is supported by educational grants from GlaxoSmithKline and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

RTP
RESEARCH
TO PRACTICE

Dr Love — Disclosures

Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.

RTP
RESEARCH
TO PRACTICE

Research To Practice CME Planning Committee Members, Staff and Reviewers

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Dr Kumar — Disclosures

Consulting/Advisory Board	Antengene, BeiGene Ltd, Oncopeptides
Consulting/Advisory Board (no personal payments)	AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Takeda Oncology
Research Funding for Clinical Trials to the Institution	AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, CARsgen Therapeutics, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Takeda Oncology, TeneoBio

RTP RESEARCH TO PRACTICE

Dr Lonial — Disclosures

Consulting Agreements	Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Takeda Oncology
Contracted Research	Celgene Corporation, Janssen Biotech Inc, Takeda Oncology

RTP
RESEARCH
TO PRACTICE

Dr Richardson — Disclosures

Advisory Committee	Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Oncopeptides, Sanofi Genzyme, Secura Bio, Takeda Oncology
Contracted Research	Bristol-Myers Squibb Company, Celgene Corporation, Oncopeptides, Takeda Oncology

RTP
RESEARCH
TO PRACTICE

Ms Gleason — Disclosures

No relevant conflicts of interest to disclose.

Ms Mangan — Disclosures

Consulting Agreements	GlaxoSmithKline, Merck
Speakers Bureau	Amgen Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Oncopeptides, Sanofi Genzyme, Takeda Oncology

RTP
RESEARCH
TO PRACTICE

Dr Richards — Disclosures

Consulting Agreements	Celgene Corporation, GlaxoSmithKline, Sanofi Genzyme, Takeda Oncology

RTP
RESEARCH
TO PRACTICE

We Encourage Clinicians in Practice to Submit Questions



Feel free to submit questions now before the program begins and throughout the program.

RTP RESEARCH TO PRACTICE

Familiarizing Yourself with the Zoom Interface

How to answer poll questions



When a poll question pops up, click your answer choice from the available options.

RTP RESEARCH TO PRACTICE

Familiarizing Yourself with the Zoom Interface

Expand chat submission box



Drag the white line above the submission box up to create more space for your message.

RTP RESEARCH TO PRACTICE

Familiarizing Yourself with the Zoom Interface

Increase chat font size



Press Command (for Mac) or Control (for PC) and the + symbol.
You may do this as many times as you need for readability.

ONCOLOGY TODAY

WITH DR NEIL LOVE

Key Presentations on Multiple Myeloma, Waldenström Macroglobulinemia and Amyloidosis from the 2020 ASH Annual Meeting

DR NATALIE CALLANDER

UNIVERSITY OF WISCONSIN CARBONE CANCER CENTER

Listen on Apple Podcasts

Spotify

Listen on Google Podcasts

13th Annual Oncology Grand Rounds

A Complimentary NCPD Live Webinar Series Held During the 46th Annual ONS Congress

Breast Cancer
Tuesday, April 20, 2021
8:30 AM – 10:00 AM ET

Non-Small Cell Lung Cancer
Tuesday, April 20, 2021
5:00 PM – 6:30 PM ET

Acute Myeloid Leukemia
Wednesday, April 21, 2021
12:00 PM – 1:00 PM ET

Colorectal and Gastroesophageal Cancers
Wednesday, April 21, 2021
4:45 PM – 5:45 PM ET

Prostate Cancer
Thursday, April 22, 2021
8:30 AM – 10:00 AM ET

Hodgkin and Non-Hodgkin Lymphomas
Thursday, April 22, 2021
5:00 PM – 6:30 PM ET

Multiple Myeloma
Tuesday, April 27, 2021
8:30 AM – 10:00 AM ET

Gynecologic Cancers
Tuesday, April 27, 2021
5:00 PM – 6:30 PM ET

Urothelial Bladder Carcinoma
Wednesday, April 28, 2021
12:00 PM – 1:00 PM ET

Chronic Lymphocytic Lymphoma
Thursday, April 29, 2021
8:30 AM – 10:00 AM ET

Chimeric Antigen Receptor T-Cell Therapy
Thursday, April 29, 2021
5:00 PM – 6:30 PM ET

RTP RESEARCH TO PRACTICE

Ask the Expert: Clinical Investigators Provide Perspectives on the Management of Renal Cell Carcinoma

In Partnership with Project Echo® and Florida Cancer Specialists

Tuesday, May 4, 2021
5:00 PM – 6:00 PM ET

Faculty

Chung-Han Lee, MD, PhD

Moderator

Neil Love, MD

Current Concepts and Recent Advances in Oncology

A Daylong Clinical Summit Hosted in Partnership with Medical Oncology Association of Southern California (MOASC)

Saturday, May 15, 2021
10:30 AM – 6:30 PM ET

RTP
RESEARCH TO PRACTICE

Saturday, May 15, 2021

10:30 AM — Breast Cancer
Ruth O'Regan, Tiffany A Traina

11:30 AM — Multiple Myeloma
Kenneth Anderson, Noopur Raje

12:50 PM — Chronic Lymphocytic Leukemia and Lymphomas
Craig Moskowitz, Jeff Sharman

1:50 PM — Genitourinary Cancers
Joaquim Bellmunt, Sumanta Kumar Pal

RTP
RESEARCH
TO PRACTICE

Saturday, May 15, 2021

3:15 PM — Gastrointestinal Cancers
Wells A Messersmith, Eileen M O'Reilly

4:15 PM — Acute Myeloid Leukemia and Myelodysplastic Syndromes
Harry Paul Erba, Rami Komrokji

5:35 PM — Lung Cancer
D Ross Camidge, Benjamin Levy

RTP
RESEARCH
TO PRACTICE

Up for Debate: Oncology Investigators Provide Their Take on Current Controversies in Patient Care

A Daylong Multitumor Educational Webinar
in Partnership with Florida Cancer Specialists

Saturday, May 22, 2021
10:15 AM – 4:15 PM ET

RTP
RESEARCH
TO PRACTICE

Saturday, May 22, 2021

10:15 AM — Lung Cancer
John V Heymach, Stephen V Liu

11:30 AM — Genitourinary Cancers
Maha Hussain, Elizabeth R Plimack

12:45 PM — Chronic Lymphocytic Leukemia and Lymphomas
Jonathan W Friedberg, Laurie H Sehn

2:00 PM — Multiple Myeloma
Irene M Ghobrial, Sagar Lonial

3:15 PM — Breast Cancer
Virginia Kaklamani, Nancy U Lin

RTP
RESEARCH
TO PRACTICE

Thank you for joining us!

NCPD credit information will be emailed to each participant shortly.

RTP
RESEARCH
TO PRACTICE

13th Annual Oncology Grand Rounds

A Complimentary NCPD Live Webinar Series
Held During the 46th Annual ONS Congress

Multiple Myeloma

Tuesday, April 27, 2021
8:30 AM – 10:00 AM ET

Medical Oncologists

Shaji K Kumar, MD
Sagar Lonial, MD
Paul G Richardson, MD

Oncology Nurse Practitioners

Charise Gleason, MSN, NP-C, AOCNP
Patricia Mangan, RN, MSN, CRNP, APN, BC
Tiffany A Richards, PhD, ANP-BC, AOCNP

Moderator

Neil Love, MD

RTP RESEARCH TO PRACTICE

Medical Oncologists

Shaji K Kumar, MD
Mark and Judy Mullins Professor of
Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Sagar Lonial, MD
Chair and Professor
Department of Hematology and
Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Paul G Richardson, MD
Clinical Program Leader and Director of
Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
RJ Corman Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Oncology Nurse Practitioners

Charise Gleason, MSN, NP-C, AOCNP
Advanced Practice Provider Chief
Winship Cancer Institute of Emory University
Adjunct Faculty, Nell Hodgson Woodruff
School of Nursing
Atlanta, Georgia

Patricia Mangan, RN, MSN, CRNP, APN, BC
Nurse Lead, Hematologic Malignancies and
Stem Cell Transplant Programs
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Tiffany A Richards, PhD, ANP-BC, AOCNP
Nurse Practitioner
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

RTP
RESEARCH
TO PRACTICE

We Encourage Clinicians in Practice to Submit Questions



Feel free to submit questions now before the program begins and throughout the program.

RTP RESEARCH TO PRACTICE

Familiarizing Yourself with the Zoom Interface

How to answer poll questions



When a poll question pops up, click your answer choice from the available options.

Current Concepts and Recent Advances in Oncology

A Daylong Clinical Summit Hosted in Partnership with Medical Oncology Association of Southern California (MOASC)

Saturday, May 15, 2021
10:30 AM – 6:30 PM ET

RTP
RESEARCH TO PRACTICE

Saturday, May 15, 2021

10:30 AM — Breast Cancer
Ruth O'Regan, Tiffany A Traina

11:30 AM — Multiple Myeloma
Kenneth Anderson, Noopur Raje

12:50 PM — Chronic Lymphocytic Leukemia and Lymphomas
Craig Moskowitz, Jeff Sharman

1:50 PM — Genitourinary Cancers
Joaquim Bellmunt, Sumanta Kumar Pal

RTP
RESEARCH
TO PRACTICE

Saturday, May 15, 2021

3:15 PM — Gastrointestinal Cancers
Wells A Messersmith, Eileen M O'Reilly

4:15 PM — Acute Myeloid Leukemia and Myelodysplastic Syndromes
Harry Paul Erba, Rami Komrokji

5:35 PM — Lung Cancer
D Ross Camidge, Benjamin Levy

RTP
RESEARCH
TO PRACTICE

Up for Debate: Oncology Investigators Provide Their Take on Current Controversies in Patient Care

A Daylong Multitumor Educational Webinar
in Partnership with Florida Cancer Specialists

Saturday, May 22, 2021
10:15 AM – 4:15 PM ET

RTP
RESEARCH
TO PRACTICE

Saturday, May 22, 2021

10:15 AM — Lung Cancer
John V Heymach, Stephen V Liu

11:30 AM — Genitourinary Cancers
Maha Hussain, Elizabeth R Plimack

12:45 PM — Chronic Lymphocytic Leukemia and Lymphomas
Jonathan W Friedberg, Laurie H Sehn

2:00 PM — Multiple Myeloma
Irene M Ghobrial, Sagar Lonial

3:15 PM — Breast Cancer
Virginia Kaklamani, Nancy U Lin

RTP
RESEARCH
TO PRACTICE

13th Annual Oncology Grand Rounds

A Complimentary NCPD Live Webinar Series Held During the 46th Annual ONS Congress

Breast Cancer
Tuesday, April 20, 2021
8:30 AM – 10:00 AM ET

Non-Small Cell Lung Cancer
Tuesday, April 20, 2021
5:00 PM – 6:30 PM ET

Acute Myeloid Leukemia
Wednesday, April 21, 2021
12:00 PM – 1:00 PM ET

Colorectal and Gastroesophageal Cancers
Wednesday, April 21, 2021
4:45 PM – 5:45 PM ET

Prostate Cancer
Thursday, April 22, 2021
8:30 AM – 10:00 AM ET

Hodgkin and Non-Hodgkin Lymphomas
Thursday, April 22, 2021
5:00 PM – 6:30 PM ET

Multiple Myeloma
Tuesday, April 27, 2021
8:30 AM – 10:00 AM ET

Gynecologic Cancers
Tuesday, April 27, 2021
5:00 PM – 6:30 PM ET

Urothelial Bladder Carcinoma
Wednesday, April 28, 2021
12:00 PM – 1:00 PM ET

Chronic Lymphocytic Lymphoma
Thursday, April 29, 2021
8:30 AM – 10:00 AM ET

Chimeric Antigen Receptor T-Cell Therapy
Thursday, April 29, 2021
5:00 PM – 6:30 PM ET

RTP RESEARCH TO PRACTICE

Medical Oncologists

Jeremy Abramson, MD
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Carey K Anders, MD
Professor of Medicine
Medical Director of the Duke Center of Brain and Spine Metastases
Duke Cancer Institute
Durham, North Carolina

Stephen M Ansell, MD, PhD
Professor of Medicine
Chair, Lymphoma Group
Mayo Clinic
Rochester, Minnesota

Johanna Bendell, MD
Chief Development Officer
Director, Drug Development Unit Nashville
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Carla Casulo, MD
Associate Professor of Medicine
Division of Hematology/Oncology
Director, Hematology/Oncology Fellowship Program
University of Rochester
Wilmot Cancer Institute
New York, New York

RTP
RESEARCH TO PRACTICE

Medical Oncologists

Daniel Catenacci, MD
Associate Professor, Department of Medicine
Section of Hematology and Oncology
Director, Interdisciplinary Gastrointestinal Oncology Program
Assistant Director, Translational Research
Comprehensive Cancer Center
The University of Chicago Medical Center and Biological Sciences
Chicago, Illinois

Robert L Coleman, MD
Chief Scientific Officer
US Oncology Research
Gynecologic Oncology
The Woodlands, Texas

Courtney D DiNardo, MD, MSCE
Associate Professor, Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Elisabeth I Heath, MD
Associate Center Director, Translational Sciences
Chair, Genitourinary Oncology Multidisciplinary Team
Professor of Oncology and Medicine
Hartmann Endowed Chair for Prostate Cancer Research
Director, Prostate Cancer Research
Karmanos Cancer Institute
Wayne State University School of Medicine
Detroit, Michigan

RTP
RESEARCH TO PRACTICE

Medical Oncologists

Thomas J Herzog, MD
Paul and Carolyn Flory Professor
Deputy Director, University of Cincinnati Cancer Center
Vice-Chair, Quality and Safety
Department of Obstetrics and Gynecology
University of Cincinnati Medical Center
Associate Director, GOG Partners
Cincinnati, Ohio

John V Heymach, MD, PhD
Professor and Chair
Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Brian T Hill, MD, PhD
Director, Lymphoid Malignancy Program
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Caron Jacobson, MD
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Shaji K Kumar, MD
Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

John P Leonard, MD
Richard T Silver Distinguished Professor of Hematology and Medical Oncology
Senior Associate Dean for Innovation and Initiatives
Executive Vice Chair, Joan and Sanford I Weill Department of Medicine
Weill Cornell Medicine
New York, New York

RTP RESEARCH TO PRACTICE

Medical Oncologists

Sagar Lonial, MD
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Kathy D Miller, MD
Ballvé-Lantero Professor
Division of Hematology/Oncology
Associate Director for Clinical Research
The Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana

John M Pagel, MD, PhD
Chief of Hematologic Malignancies Program
Center for Blood Disorders and Stem Cell Transplantation
Swedish Cancer Institute
Seattle, Washington

Paul K Paik, MD
Associate Attending Physician
Clinical Director, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Daniel P Petrylak, MD
Professor of Internal Medicine
(Medical Oncology) and Urology
Yale School of Medicine
New Haven, Connecticut

Zofia Piotrowska, MD, MHS
Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts

RTP
RESEARCH TO PRACTICE

Medical Oncologists

Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Paul G Richardson, MD
Clinical Program Leader and Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
RJ Corman Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Charles J Ryan, MD
Professor of Medicine
BJ Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
University of Minnesota
Minneapolis, Minnesota

A Oliver Sartor, MD
CE and Bernadine Laborde Professor for Cancer Research
Medical Director, Tulane Cancer Center
Assistant Dean for Oncology
Tulane Medical School
New Orleans, Louisiana

Eytan M Stein, MD
Assistant Attending Physician
Director, Program for Drug Development in Leukemia
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Mary-Ellen Taplin, MD
Professor of Medicine
Harvard School of Medicine
Dana-Farber Cancer Institute
Boston, Massachusetts

RTP
RESEARCH TO PRACTICE

Medical Oncologists

Krishnansu S Tewari, MD
Professor and Division Director
Division of Gynecologic Oncology
University of California, Irvine
Irvine, California

Jennifer Woyach, MD
Professor
Division of Hematology
Department of Internal Medicine
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio

Sara M Tolaney, MD, MPH
Associate Director
Susan F Smith Center for Women's Cancers
Director of Clinical Trials, Breast Oncology
Director of Breast Immunotherapy Clinical Research
Senior Physician
Breast Oncology Program
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

RTP
RESEARCH
TO PRACTICE

Oncology Nurse Practitioners

Paula J Anastasia, MN, RN, AOCN
GYN Oncology Advanced Practice Nurse
University of California, Los Angeles
Los Angeles, California

Courtney Arn, CNP
The James Cancer Hospital and
Solove Research Institute
The Ohio State University
Columbus, Ohio

Monica Averia, MSN, AOCNP, NP-C
Oncology Nurse Practitioner
USC Norris Cancer Center
Los Angeles, California

Lesley Camille Ballance, MSN, FNP-BC
Sarah Cannon Center for Blood Cancer
Tennessee Oncology
Nashville, Tennessee

Kristen E Battiato, AGNP-C
Advanced Practice Providers
Memorial Sloan Kettering Cancer Center
New York, New York

Kathy D Burns, RN, MSN, AGACNP-BC, OCN
GU Medical Oncology
City of Hope Comprehensive Cancer Center
Duarte, California

Gretchen Santos Fulgencio, MSN, FNP-BC
University of California, San Francisco
Berkeley, California

Ilene Galinsky, NP
Senior Adult Leukemia Program Research
Nurse Practitioner
Dana-Farber Cancer Institute
Boston, Massachusetts

RTP
RESEARCH
TO PRACTICE

Oncology Nurse Practitioners

Jacklyn Gideon, MSN, AGPCNP-BC
Advanced Practice Provider
Lead Apheresis APP
Hematopoietic Cellular Therapy Program
Section of Hematology/Oncology
The University of Chicago Medicine and
Biological Sciences
Chicago, Illinois

Charise Gleason, MSN, NP-C, AOCNP
Advanced Practice Provider Chief
Winship Cancer Institute of Emory University
Adjunct Faculty, Nell Hodgson Woodruff
School of Nursing
Atlanta, Georgia

Sonia Glennie, ARNP, MSN, OCN
Swedish Cancer Institute Center for
Blood Disorders
Seattle, Washington

Kelly EH Goodwin, MSN, RN, ANP-BC
Thoracic Cancer Center
Massachusetts General Hospital
Boston, Massachusetts

Allie Hershey, MSN, RN, ANP-BC, AOCNP
Oncology Nurse Practitioner, Breast Oncology
Susan F Smith Center for Women's Cancers
Dana-Farber Cancer Institute
Boston, Massachusetts

Corinne Hoffman, MS, APRN-CNP, AOCNP
Nurse Practitioner, Hematology
The James Comprehensive Cancer Center
The Ohio State University Wexner Medical Center
Columbus, Ohio

RTP
RESEARCH
TO PRACTICE

Oncology Nurse Practitioners

Robin Klebig, APRN, CNP, AOCNP
Nurse Practitioner
Assistant Professor of Medicine
Division of Hematology
Mayo Clinic
Rochester, Minnesota

Kelly Leonard, MSN, FNP-BC
Family Nurse Practitioner
Dana-Farber Cancer Institute
Boston, Massachusetts

Patricia Mangan, RN, MSN, CRNP, APN, BC
Nurse Lead, Hematologic Malignancies and
Stem Cell Transplant Programs
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Brenda Martone, MSN, NP-BC, AOCNP
Northwestern Medicine
Northwestern Memorial Hospital
Chicago, Illinois

Alli McClanahan, MSN, APRN, ANP-BC
Nurse Practitioner
Division of Hematology
Mayo Clinic
Rochester, Minnesota

Jessica Mitchell, APRN, CNP, MPH
Assistant Professor of Oncology
Mayo Clinic College of Medicine and Science
Rochester, Minnesota

Mollie Moran, APRN-CNP, AOCNP
The James Cancer Hospital and Solove
Research Institute
The Ohio State University
Columbus, Ohio

RTP
RESEARCH
TO PRACTICE

Oncology Nurse Practitioners

Tara Plues, APRN, MSN
Hematology and Medical Oncology
Cleveland Clinic
Cleveland, Ohio

Kimberly A Spickes, MNSc, RN, APRN, OCN, ACNP-BC
Nurse Practitioner
UAMS Division of Gynecologic Oncology
University of Arkansas for Medical Sciences
Little Rock, Arkansas

Tiffany A Richards, PhD, ANP-BC, AOCNP
Nurse Practitioner
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Ronald Stein, JD, MSN, NP-C, AOCNP
Clinical Instructor of Medicine
USC Norris Comprehensive Cancer Center
Los Angeles, California

Victoria Sherry, DNP, CRNP, AOCNP
Oncology Nurse Practitioner for Thoracic Malignancies
Abramson Cancer Center
Perelman Center for Advanced Medicine
University of Pennsylvania Medical Center
Faculty, University of Pennsylvania School of Nursing
Philadelphia, Pennsylvania

Elizabeth Zerante, MS, AGACNP-BC
APN Inpatient Hematopoietic Cellular Therapy Service
University of Chicago Medicine
Chicago, Illinois

RTP
RESEARCH TO PRACTICE

Oncology Grand Rounds Nursing Webinar Series

Monday	Tuesday	Wednesday	Thursday	Friday
19	20 Breast Ca 8:30 AM Lung Ca 5:00 PM	21 AML 12:00 PM CRC and GE Ca 4:45 PM	22 Prostate Ca 8:30 AM Lymphomas 5:00 PM	23
26	27 Multiple Myeloma 8:30 AM Gynecologic Ca 5:00 PM	28 Bladder Ca 12:00 PM	29 CLL 8:30 AM CAR-T 5:00 PM	30

RTP RESEARCH TO PRACTICE






The Birmingham News

13th Annual Oncology Grand Rounds

Oncology Nurse Practitioners

Case Presentations

- Key patient-education issues
- Biopsychosocial considerations:
  - Family/loved ones
  - The bond that heals

Clinical Investigators

Oncology Strategy

- New agents and regimens
- Predictive biomarkers
- Ongoing research and implications

RTP
RESEARCH
TO PRACTICE

13th Annual Oncology Grand Rounds

A Complimentary NCPD Live Webinar Series
Held During the 46th Annual ONS Congress

Multiple Myeloma

Tuesday, April 27, 2021
8:30 AM – 10:00 AM ET

Medical Oncologists

Shaji K Kumar, MD
Sagar Lonial, MD
Paul G Richardson, MD

Oncology Nurse Practitioners

Charise Gleason, MSN, NP-C, AOCNP
Patricia Mangan, RN, MSN, CRNP, APN, BC
Tiffany A Richards, PhD, ANP-BC, AOCNP

Moderator

Neil Love, MD

RTP RESEARCH TO PRACTICE


Charise Gleason, MSN, NP-C, AOCNP


Patricia Mangan, RN MSN CRNP APN, BC


Tiffany A Richards, PhD, ANP-BC, AOCNP

Agenda

Module 1: Newly Diagnosed Multiple Myeloma

- Case 1 (Dr Richards): A 73-year-old woman who receives daratumumab, lenalidomide and dexamethasone
- Case 2 (Ms Gleason): A 78-year-old woman who receives kyphoplasty for newly diagnosed multiple myeloma
- Case 3 (Ms Mangan): A 66-year-old woman with newly diagnosed multiple myeloma and lytic lesions

Module 2: Multiagent-Refractory Multiple Myeloma

- Case 4 (Ms Gleason): A 78-year-old woman with t(11;14) multiple regimen-relapsed multiple myeloma
- Case 5 (Ms Mangan): A 77-year-old man with t(11;14) multiple regimen-relapsed multiple myeloma

Module 3: CAR T-Cell Therapy

- Case 6 (Dr Richards): A 56-year-old woman with multiple regimen-relapsed multiple myeloma
- Case 7 (Ms Gleason): A 62-year-old man with multiple regimen-relapsed multiple myeloma

RTP
RESEARCH
TO PRACTICE

Ms Mangan: Perspective on the evolution of the multiple myeloma treatment landscape

RTP
RESEARCH
TO PRACTICE

Agenda

Module 1: Newly Diagnosed Multiple Myeloma

- Case 1 (Dr Richards): A 73-year-old woman who receives daratumumab, lenalidomide and dexamethasone
- Case 2 (Ms Gleason): A 78-year-old woman who receives kyphoplasty for newly diagnosed multiple myeloma
- Case 3 (Ms Mangan): A 66-year-old woman with newly diagnosed multiple myeloma and lytic lesions

Module 2: Multiagent-Refractory Multiple Myeloma

- Case 4 (Ms Gleason): A 78-year-old woman with t(11;14) multiple regimen-relapsed multiple myeloma
- Case 5 (Ms Mangan): A 77-year-old man with t(11;14) multiple regimen-relapsed multiple myeloma

Module 3: CAR T-Cell Therapy

- Case 6 (Dr Richards): A 56-year-old woman with multiple regimen-relapsed multiple myeloma
- Case 7 (Ms Gleason): A 62-year-old man with multiple regimen-relapsed multiple myeloma

RTP
RESEARCH
TO PRACTICE

Case Presentation – A 73-year-old woman who receives daratumumab, lenalidomide and dexamethasone (Part 1)

Dr Richards

- 2020: Retired nurse diagnosed with IgG kappa standard-risk multiple myeloma
  - Daily steroids x 1 month by outside provider → tapered off
- Patient not interested in undergoing transplant
- Daratumumab/lenalidomide/dexamethasone
  - Syncopal episode → treatment hold
  - Great response after 1 dose of daratumumab, 4 doses of lenalidomide
- Observation x 2-3 months → increase in light chains → daratumumab

RTP RESEARCH TO PRACTICE

Case Presentation – A 73-year-old woman who receives daratumumab, lenalidomide and dexamethasone (Part 2)

Dr Richards

- 2020: Retired nurse diagnosed with IgG kappa standard-risk multiple myeloma
  - Daily steroids x 1 month by outside provider → tapered off
- Patient not interested in undergoing transplant
- Daratumumab/lenalidomide/dexamethasone
  - Syncopal episode → treatment hold
  - Great response after 1 dose of daratumumab, 4 doses of lenalidomide
- Observation x 2-3 months → increase in light chains → daratumumab
- ***Workup and education for patients beginning daratumumab***

RTP RESEARCH TO PRACTICE

Ms Mangan: Patient education on subcutaneous daratumumab

Case Presentation – A 78-year-old woman who receives kyphoplasty for newly diagnosed multiple myeloma

Ms Gleason

- Retired teacher who relocated to live with her daughter was diagnosed with IgG kappa standard-risk multiple myeloma soon after moving
- Daratumumab/lenalidomide/dexamethasone → maintenance lenalidomide
- Underwent kyphoplasty for a vertebral fracture
- Pain management; use of complementary strategies to ameliorate pain

RTP
RESEARCH
TO PRACTICE

The antitumor component of autologous stem cell transplantation (ASCT) is…

1. Re-transplanted marrow cells
2. Chemotherapy
3. The patient's T cells
4. I don't know

RTP
RESEARCH
TO PRACTICE

The antitumor component of chimeric antigen receptor (CAR) T-cell therapy is…

1. Re-transplanted marrow cells
2. Chemotherapy
3. The patient's T cells
4. I don't know

RTP
RESEARCH
TO PRACTICE

In general, which patients with multiple myeloma (MM) who are transplant eligible receive post-ASCT maintenance therapy such as lenalidomide?

1. Most or all
2. Most or all except for those who are in complete remission
3. Most or all except for those who are minimal residual disease negative
4. Mainly patients with high-risk MM (eg, 17p deletion)
5. I don’t know

RTP
RESEARCH
TO PRACTICE

Patients with del(17p) MM often receive post-ASCT transplant maintenance with…

1. An IMiD alone (eg, lenalidomide)
2. An IMiD and a proteasome inhibitor (eg, lenalidomide/bortezomib)
3. I don’t know

RTP
RESEARCH
TO PRACTICE

Case Presentation – A 66-year-old woman with newly diagnosed multiple myeloma and lytic lesions (Part 1)

Ms Mangan

- Former NICU nurse who presented to emergency room with worsening back pain after lifting lawn furniture
- Diagnosed with IgG kappa multiple myeloma, anemia and an L2 compression fracture with soft tissue component and other lytic lesions throughout skeleton
- Induction therapy: RVd with XRT and zoledronic acid → maintenance lenalidomide
- Peripheral neuropathy associated with bortezomib

RTP RESEARCH TO PRACTICE

Case Presentation – A 66-year-old woman with newly diagnosed multiple myeloma and lytic lesions (Part 2)

Ms Mangan

- Former NICU nurse who presented to emergency room with worsening back pain after lifting lawn furniture
- Diagnosed with IgG kappa multiple myeloma, anemia and an L2 compression fracture with soft tissue component and other lytic lesions throughout skeleton
- Induction therapy: RVd with XRT and zoledronic acid → maintenance lenalidomide
- Peripheral neuropathy associated with bortezomib
- ***Dermatologic side effects associated with lenalidomide***

RTP RESEARCH TO PRACTICE

Case Presentation – A 66-year-old woman with newly diagnosed multiple myeloma and lytic lesions (Part 3)

Ms Mangan

- Former NICU nurse who presented to emergency room with worsening back pain after lifting lawn furniture
- Diagnosed with IgG kappa multiple myeloma, anemia and an L2 compression fracture with soft tissue component and other lytic lesions throughout skeleton
- Induction therapy: RVD with XRT and zoledronic acid → maintenance lenalidomide
- Peripheral neuropathy associated with bortezomib
- Dermatologic side effects associated with lenalidomide
- ***In remission with good quality of life on maintenance lenalidomide***

RTP RESEARCH TO PRACTICE

Updated Analysis of Daratumumab plus Lenalidomide and Dexamethasone (D-Rd) versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 MAIA Study

Kumar SK et al.

ASH 2020;Abstract 2276.

RTP
RESEARCH
TO PRACTICE

MAIA: Updated PFS (Median Follow-Up 48 Months)



Kumar SK et al. ASH 2020;Abstract 2276.

RTP RESEARCH TO PRACTICE

MAIA: Updated Response



Kumar SK et al. ASH 2020;Abstract 2276.

RTP RESEARCH TO PRACTICE

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

Shaji K Kumar, Susanna J Jacobus, Adam D Cohen, Matthias Weiss, Natalie Callander, Avina K Singh, Terri L Parker, Alexander Menter, Xuezhong Yang, Benjamin Parsons, Pankaj Kumar, Prashant Kapoor, Aaron Rosenberg, Jeffrey A Zonder, Edward Faber Jr, Sagar Lonial, Kenneth C Anderson, Paul G Richardson, Robert Z Orlowski, Lynne I Wagner, S Vincent Rajkumar

***Lancet Oncol* 2020;21(10):1317-30**

RTP RESEARCH TO PRACTICE

ENDURANCE (E1A11): Primary PFS Endpoint (Second Interim Analysis)



- Median OS has not been reached in either group at median follow-up of 24 months; patients will continue on long-term follow-up for overall survival

Kumar SK et al. *Lancet Oncol* 2020;21(10):1317-30.

RTP RESEARCH TO PRACTICE

ENDURANCE (E1A11): Treatment-Emergent Adverse Events of Interest



Cardiac, pulmonary and renal

Peripheral neuropathy*

* Grades 1-2 not required reporting

Berdeja JG. ASCO 2020 Discussant.

Daratumumab (DARA) plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin After 12 Months of Maintenance Therapy

Kaufman JL et al.

ASH 2020;Abstract 549.

RTP
RESEARCH
TO PRACTICE

Responses Deepened over Time[a]



- *Results for end of induction, ASCT, and consolidation are based on a median follow up of 13.5 months at the primary analysis*
- *Median follow up at 12-months-of-maintenance therapy cutoff was 27.4 months*

Response rates and depths were greater for D-RVd at all time points

PR, partial response. SD/PD/NE, stable disease/progressive disease/not evaluable. [a]Data are shown for the response-evaluable population. [b]*P* values (2-sided) were calculated using the Cochran–Mantel–Haenszel chi-square test.

Kaufman JL et al. ASH 2020;Abstract 549.

RTP RESEARCH TO PRACTICE

Durable MRD (10^{-5}) Negativity[a] Lasting ≥6 and ≥12 Months





- *Among patients who achieved MRD negative (10^{-5}) status, sustained MRD negativity lasting ≥12 months was noted in 30/65 (46.2%) and 3/28 (10.7%) patients*

D-RVd improved rates of sustained MRD negativity versus RVd

[a]The threshold of MRD negativity was defined as 1 tumor cell per 10^5 white cells. MRD status is based on the assessment of bone marrow aspirates by NGS in accordance with International Myeloma Working Group criteria. Median follow-up was 27.4 months, and MRD-negativity rates are among the ITT population. [b]*P* values were calculated using the Fisher's exact test.

Kaufman JL et al. ASH 2020;Abstract 549.

RTP RESEARCH TO PRACTICE

Most Common Infections with First Onset during Maintenance Therapy (Cycles 7+)[a]

Patients, n (%)	D-RVd (D-R maintenance, n = 89)		RVd (R maintenance, n = 71)	
	Any grade	Grade 3/4	Any grade	Grade 3/4
Most common (>5%) infections				
Upper respiratory tract infection	47 (53)	4 (4)	29 (41)	2 (3)
Pneumonia	12 (13)	5 (6)	11 (15)	9 (13)
Sinusitis	9 (10)	0	7 (10)	0
Influenza	9 (10)	0	5 (7)	0
Nasopharyngitis	9 (10)	0	1 (1)	0
Urinary tract infection	8 (9)	0	1 (1)	0
Bronchitis	7 (8)	1 (1)	5 (7)	1 (1)
Cellulitis	7 (8)	1 (1)	2 (3)	1 (1)

Similar rates of any grade and grade 3/4 infections occurred for D-RVd vs RVd

[a]Any grade TEAEs that occurred in >5% of patients in either group are listed. The safety analysis population included all randomized patients who received ≥1 dose of the study treatment; analysis was according to treatment received.

Kaufman JL et al. ASH 2020;Abstract 549.

RTP RESEARCH TO PRACTICE

FDA Approval of Subcutaneous Daratumumab (Daratumumab and Hyaluronidase-fihj) for Newly Diagnosed or Relapsed/Refractory MM

Press Release – May 1, 2020

"On May 1, 2020, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj for adult patients with newly diagnosed or relapsed/refractory multiple myeloma. This new product allows for subcutaneous dosing of daratumumab."

Daratumumab and hyaluronidase-fihj is approved for certain indications that intravenous daratumumab had previously received.

Efficacy of daratumumab and hyaluronidase-fihj (monotherapy) was evaluated in COLUMBA (NCT03277105), an open-label noninferiority trial randomly assigning 263 patients to daratumumab and hyaluronidase-fihj and 259 to intravenous daratumumab.

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-daratumumab-and-hyaluronidase-fihj-multiple-myeloma

RTP RESEARCH TO PRACTICE

Lancet Haematol 2020;7:e370–80

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

Maria-Victoria Mateos, Hareth Nahi, Wojciech Legiec, Sebastian Grosicki, Vladimir Vorobyev, Ivan Spicka, Vania Hungria, Sibirina Korenkova, Nizar Bahlis, Max Flogegard, Joan Bladé, Philippe Moreau, Martin Kaiser, Shinsuke Iida, Jacob Laubach, Hila Magen, Michele Cavo, Cyrille Hulin, Darrell White, Valerio De Stefano, Pamela L Clemens, Tara Masterson, Kristen Lantz, Lisa O'Rourke, Christoph Heuck, Xiang Qin, Dolly A Parasrampuria, Zhilong Yuan, Steven Xu, Ming Qi, Saad Z Usmani

COLUMBA: Subcutaneous versus Intravenous Daratumumab

Progression-Free Survival



Overall Survival



(Median follow-up 7.5 months)

Mateos MV et al. *Lancet Haematol* 2020;7(5):e370-80.

RTP RESEARCH TO PRACTICE

Agenda

Module 1: Newly Diagnosed Multiple Myeloma

- Case 1 (Dr Richards): A 73-year-old woman who receives daratumumab, lenalidomide and dexamethasone
- Case 2 (Ms Gleason): A 78-year-old woman who receives kyphoplasty for newly diagnosed multiple myeloma
- Case 3 (Ms Mangan): A 66-year-old woman with newly diagnosed multiple myeloma and lytic lesions

Module 2: Multiagent-Refractory Multiple Myeloma

- Case 4 (Ms Gleason): A 78-year-old woman with t(11;14) multiple regimen-relapsed multiple myeloma
- Case 5 (Ms Mangan): A 77-year-old man with t(11;14) multiple regimen-relapsed multiple myeloma

Module 3: CAR T-Cell Therapy

- Case 6 (Dr Richards): A 56-year-old woman with multiple regimen-relapsed multiple myeloma
- Case 7 (Ms Gleason): A 62-year-old man with multiple regimen-relapsed multiple myeloma

RTP
RESEARCH
TO PRACTICE

The primary safety concern with belantamab mafodotin is…

1. Renal toxicity
2. Hepatic toxicity
3. Ophthalmic toxicity
4. Peripheral neuropathy
5. I don’t know

RTP
RESEARCH
TO PRACTICE

Case Presentation – A 78-year-old woman with t(11;14) multiple regimen-relapsed multiple myeloma (Part 1)

Ms Gleason

- Slowly progressing myeloma whose disease has progressed on several regimens, including venetoclax
- Treated with belantamab mafodotin on the DREAMM-4 clinical trial → 3-year response

RTP
RESEARCH
TO PRACTICE

Case Presentation – A 78-year-old woman with t(11;14) multiple regimen-relapsed multiple myeloma (Part 2)

Ms Gleason

- Slowly progressing myeloma whose disease has progressed on several regimens, including venetoclax
- Treated with belantamab mafodotin on the DREAMM-4 clinical trial → 3-year response
- ***Vision issues associated with belantamab mafodotin***

RTP RESEARCH TO PRACTICE

Case Presentation – A 77-year-old man with t(11;14) multiple regimen-relapsed multiple myeloma

Ms Mangan

- Diagnosed with multiple myeloma 6 months after a CVA
- Front-line therapy: Bortezomib/dexamethasone → ASCT → Maintenance bortezomib
- Subsequent treatments: Lenalidomide/dexamethasone (Rd), Ixazomib/Rd, Ixazomib/pomalidomide/dexamethasone
- Venetoclax/carfilzomib/dexamethasone – t(11;14)
- Belantamab mafodotin, with rapid response
  - Ocular toxicity
  - Resolution of ocular toxicity, mild drop in platelets, transient fever

RTP
RESEARCH
TO PRACTICE

Belantamab Mafodotin: Anti-BCMA Antibody-Drug Conjugate

- B-cell maturation factor (BCMA) expression is restricted to B cells at later stages of differentiation and is required for survival of plasma cells
- BCMA is broadly expressed at variable levels on malignant plasma cells
- Belantamab mafodotin is a humanized, afucosylated IgG1 anti-BCMA antibody conjugated to microtubule disrupting agent MMAF via a stable, protease-resistant maleimidocaproyl linker



Fc region of the antibody	• **Target specific** • **Enhanced ADCC**
Linker	• **Stable in circulation**
Drug	• **MMAF (non cell permeable, highly potent auristatin)**

Mechanisms of action:
- ADC mechanism
- ADCC mechanism
- Immunogenic cell death
- BCMA receptor signaling inhibition

Tai YT et al. *Blood* 2014;123(20):3128-38.

RTP RESEARCH TO PRACTICE

FDA Grants Accelerated Approval to Belantamab Mafodotin-blmf for Multiple Myeloma

Press Release – August 5, 2020

"The Food and Drug Administration granted accelerated approval to belantamab mafodotin-blmf for adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

Belantamab mafodotin-blmf was evaluated in DREAMM-2 (NCT 03525678), an open-label, multicenter trial. Patients received either belantamab mafodotin-blmf, 2.5 mg/kg or 3.4 mg/kg intravenously, once every 3 weeks until disease progression or unacceptable toxicity.

Efficacy was based on overall response rate (ORR) and response duration, as evaluated by an independent review committee using the International Myeloma Working Group uniform response criteria. The ORR was 31%. Seventy-three percent of responders had response durations ≥6 months. These results were observed in patients receiving the recommended dose of 2.5 mg/kg.

The prescribing information includes a Boxed Warning stating belantamab mafodotin-blmf causes changes in the corneal epithelium resulting in alterations in vision, including severe vision loss and corneal ulcer, and symptoms, such as blurred vision and dry eyes. Ophthalmic exams at baseline, prior to each dose, and promptly for worsening symptoms should be conducted."

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma

RTP RESEARCH TO PRACTICE

DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) – 1-Year Outcomes By Prior Therapies

Lonial S et al.

ASH 2020;Abstract 1417.

RTP
RESEARCH
TO PRACTICE

DREAMM-2: Single-Agent Belantamab Mafodotin Efficacy Outcomes

	Patients with 3-6 prior therapies (n = 47)	Patients with ≥7 prior therapies (n = 50)
ORR	34%	30%
Median DoR	11.0 mo	13.1 mo
Probability of DoR ≥6 months	63%	73%
Median PFS	2.9 mo	2.2 mo
Probability of PFS at 6 months	35%	30%

ORR = overall response rate; DoR = duration of response; PFS = progression-free survival

Lonial S et al. ASH 2020;Abstract 1417.

RTP RESEARCH TO PRACTICE

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Popat R et al.

ASH 2020;Abstract 1419.

RTP
RESEARCH
TO PRACTICE

DREAMM-6: Belantamab Mafodotin + Vd
Clinical Activity

- Response was evaluable in all patients:
  - ORR = 78%
  - VGPR = 50%
  - PR = 28%
  - SD = 17%
  - CBR = 83%
- Median DoR = not reached (median 18.2 weeks on treatment)

Popat R et al. ASH 2020;Abstract 1419.

RTP RESEARCH TO PRACTICE

DREAMM-6: Overview of Adverse Events

Patients with AE, n (%)	Belantamab mafodotin 2.5 mg/kg single + Vd (N = 18)
AEs related to study treatment	18 (100%)
Grade 3/4 AE	16 (89%)
AEs leading to permanent discontinuation of a study treatment	5 (28%)
AEs leading to permanent discontinuation of belamaf	0
AEs leading to dose reductions	13 (72%)
Corneal events	7 (39%)
Thrombocytopenia	6 (33%)
AEs leading to dose interruption/delay	18 (100%)
Corneal events	15 (83%)
Thrombocytopenia	7 (39%)
Any serious AE (SAE)	12 (67%)
Fatal SAE	0
SAEs related to study treatment	5 (28%)

Popat R et al. ASH 2020;Abstract 1419.

RTP RESEARCH TO PRACTICE

Anti-CD38 Antibodies: Mechanism of Action, Structural and Pharmacologic Similarities and Differences

Fc-dependent immune effector mechanisms and direct effects **Immunomodulatory effects**



Mechanism of action	Daratumumab	Isatuximab
Origin, isotype	Human IgG-kappa	Chimeric IgG1-kappa
CDC	+++	+
ADCC	++	++
ADCP	+++	Not determined
PCD direct	—	++
PCD cross linking	+++	+++
Modulation ectoenzyme function	+	+++

van de Donk NWCJ et al. *Blood* 2018;131(1):13-29.

RTP RESEARCH TO PRACTICE

Selinexor is associated with significant…

1. Cytopenias
2. Gastrointestinal side effects
3. Peripheral neuropathy
4. I don’t know

RTP
RESEARCH
TO PRACTICE

Selinexor Mechanism of Action



- Exportin 1 (XPO1) is the major nuclear export protein for tumor suppressor proteins (TSPs), the glucocorticoid receptor (GR) and eIF4E-bound oncoprotein mRNAs (c-myc, BCL2, BCL-xL and cyclins).
- XPO1 is overexpressed in MM and its levels often correlate with poor prognosis.
- Selinexor is a first-in-class XPO1 inhibitor that induces nuclear retention and activation of TSPs and the GR in the presence of steroids and suppresses oncoprotein expression.

Bahlis N et al. EHA 2016;Abstract P277.

RTP RESEARCH TO PRACTICE

FDA Approves Selinexor in Combination with Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma

Press Release – December 18, 2020

"The Food and Drug Administration approved selinexor in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

FDA granted selinexor accelerated approval in 2019 in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

Efficacy of selinexor in combination with bortezomib and dexamethasone was evaluated in the BOSTON Trial (KCP-330-023, NCT03110562), a randomized (1:1) open-label, multicenter, active comparator-controlled trial in patients with RRMM who had previously received at least one and at most three prior therapies."

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-selinexor-refractory-or-relapsed-multiple-myeloma

Lancet 2020;396:1563-73

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Sebastian Grosicki, Maryana Simonova, Ivan Spicka, Ludek Pour, Iryrna Kriachok, Maria Gavriatopoulou, Halyna Pylypenko, Holger W Auner, Xavier Leleu, Vadim Doronin, Ganna Usenko, Nizar J Bahlis, Roman Hajek, Reuben Benjamin, Tuphan K Dolai, Dinesh K Sinha, Christopher P Venner, Mamta Garg, Mercedes Gironella, Artur Jurczyszyn, Pawel Robak, Monica Galli, Craig Wallington-Beddoe, Atanas Radinoff, Galina Salogub, Don A Stevens, Supratik Basu, Anna M Liberati, Hang Quach, Vesselina S Goranova-Marinova, Jelena Bila, Eirini Katodritou, Hanna Oliynyk, Sybiryna Korenkova, Jeevan Kumar, Sundar Jagannath, Phillipe Moreau, Moshe Levy, Darrell White, Moshe E Gatt, Thierry Facon, Maria V Mateos, Michele Cavo, Donna Reece, Larry D Anderson Jr, Jean-Richard Saint-Martin, Jacqueline Jeha, Anita A Joshi, Yi Chai, Lingling Li, Vishnuvardhan Peddagali, Melina Arazy, Jatin Shah, Sharon Shacham, Michael G Kauffman, Meletios A Dimopoulos, Paul G Richardson, Sosana Delimpasi**

RTP RESEARCH TO PRACTICE

BOSTON: Progression-Free Survival (ITT)



	Selinexor - VD	VD	HR (*p*-value)
Median PFS	11.9 mo	9.5 mo	0.70 (0.0075)

Number at risk (number censored)

Selinexor, bortezomib, and dexamethasone	195 (0)	187 (5)	175 (12)	152 (21)	135 (31)	117 (37)	106 (42)	89 (50)	79 (57)	76 (59)	69 (63)	64 (66)	57 (71)	51 (73)	45 (76)	41 (80)	35 (83)	27 (89)	26 (90)	22 (94)	19 (97)	14 (102)	9 (106)	7 (108)	6 (109)	4 (111)	2 (113)
Bortezomib and dexamethasone	207 (0)	187 (8)	175 (10)	152 (15)	138 (20)	127 (22)	111 (29)	100 (32)	90 (37)	81 (37)	66 (41)	59 (43)	56 (44)	53 (45)	49 (47)	42 (52)	35 (55)	26 (60)	20 (65)	16 (69)	10 (73)	8 (75)	5 (78)	4 (79)	3 (80)	3 (80)	2 (81)

Grosicki S et al. *Lancet* 2020;396(10262):1563-73.

RTP RESEARCH TO PRACTICE

Melphalan Flufenamide (Melflufen): Mechanism of Action

Melflufen is an investigational first-in-class peptide-drug conjugate (PDC) that **targets aminopeptidases and rapidly releases alkylating agents into tumor cells.**[1-5]



- In the pivotal phase 2 HORIZON study (OP-106), the activity of melflufen plus dexamethasone was further shown in heavily pretreated RRMM patients refractory to pomalidomide and/or anti-CD38 mAb therapy, with acceptable safety[6]
  - ORR was 29%; median PFS was 4.2 months, and median OS was 11.6 months
  - Grade 3/4 hematologic AEs were common (mainly neutropenia [79%], thrombocytopenia [76%], and anemia [71%]) but clinically manageable; nonhematologic AEs were infrequent

AE, adverse event; mAb, monoclonal antibody; ORR, overall response rate; OS, overall survival; PFS, progression-rate survival; RRMM, relapsed/refractory multiple myeloma.

Ocio E et al. ASH 2020;Abstract 417.

RTP RESEARCH TO PRACTICE

FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma

Press Release – February 26, 2021

"On February 26, 2021, the Food and Drug Administration granted accelerated approval to melphalan flufenamide in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38 directed monoclonal antibody.

Efficacy was evaluated in HORIZON (NCT02963493), a multicenter, single-arm trial. Eligible patients were required to have relapsed refractory multiple myeloma. Patients received melphalan flufenamide 40 mg intravenously on day 1 and dexamethasone 40 mg orally (20 mg for patients ≥75 years of age) on day 1, 8, 15 and 22 of each 28-day cycle until disease progression or unacceptable toxicity.

Efficacy was evaluated in a subpopulation of 97 patients who received four or more prior lines of therapy and were refractory to at least one proteasome inhibitor, one immunomodulatory agent, and a CD38-directed antibody. The main efficacy outcome measure was overall response rate (ORR) and duration of response (DOR) assessed by investigators according to the International Myeloma Working Group (IMWG) Criteria. The ORR was 23.7% (95% CI: 15.7, 33.4) and median DOR 4.2 months (95% CI: 3.2, 7.6)."

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-melphalan-flufenamide-relapsed-or-refractory-multiple-myeloma

RTP RESEARCH TO PRACTICE

Agenda

Module 1: Newly Diagnosed Multiple Myeloma

- Case 1 (Dr Richards): A 73-year-old woman who receives daratumumab, lenalidomide and dexamethasone
- Case 2 (Ms Gleason): A 78-year-old woman who receives kyphoplasty for newly diagnosed multiple myeloma
- Case 3 (Ms Mangan): A 66-year-old woman with newly diagnosed multiple myeloma and lytic lesions

Module 2: Multiagent-Refractory Multiple Myeloma

- Case 4 (Ms Gleason): A 78-year-old woman with t(11;14) multiple regimen-relapsed multiple myeloma
- Case 5 (Ms Mangan): A 77-year-old man with t(11;14) multiple regimen-relapsed multiple myeloma

Module 3: CAR T-Cell Therapy

- Case 6 (Dr Richards): A 56-year-old woman with multiple regimen-relapsed multiple myeloma
- Case 7 (Ms Gleason): A 62-year-old man with multiple regimen-relapsed multiple myeloma

RTP
RESEARCH
TO PRACTICE

Case Presentation – A 56-year-old woman with multiple regimen-relapsed multiple myeloma

Dr Richards

- A woman with standard-risk myeloma and multiple regimen-relapsed disease
- Developed skin and pancreatic plasmacytomas
- Treated with idecabtagene vicleucel and developed Grade 2 CRS
- Complete resolution of skin plasmacytomas at 30-day response evaluation

RTP
RESEARCH
TO PRACTICE

Dr Richards: Patient education on receiving CAR T-cell therapy

RTP
RESEARCH
TO PRACTICE

Dr Richards: Quality of life benefits from remaining off therapy

Case Presentation – A 62-year-old man with multiple regimen-relapsed multiple myeloma (Part 1)

Ms Gleason

- Former flight attendant and volunteer firefighter with standard-risk myeloma that has relapsed on 5 prior regimens, including:
  - RVd → ASCT → maintenance lenalidomide
  - Pomalidomide/daratumumab/dexamethasone
  - Carfilzomib/cyclophosphamide/dexamethasone
  - V-DCEP (bortezomib/dexamethasone/cyclophosphamide/etoposide/cisplatin)
  - Pomalidomide/elotuzumab/dexamethasone
- Developed palpable plasmacytomas
- Treated with orvacabtagene autoleucel

RTP
RESEARCH
TO PRACTICE

Case Presentation – A 62-year-old man with multiple regimen-relapsed multiple myeloma (Part 2)

Ms Gleason

- Former flight attendant and volunteer firefighter with standard-risk myeloma that has relapsed on 5 prior regimens, including:
  - RVd → ASCT → maintenance lenalidomide
  - Pomalidomide/daratumumab/dexamethasone
  - Carfilzomib/cyclophosphamide/dexamethasone
  - V-DCEP (bortezomib/dexamethasone/cyclophosphamide/etoposide/cisplatin)
  - Pomalidomide/elotuzumab/dexamethasone
- Developed palpable plasmacytomas
- ***Caring for a patient through the highs and lows of their disease***

RTP RESEARCH TO PRACTICE

An early indicator of neurotoxicity from CAR T-cell therapy is…

1. Somnolence
2. Seizures
3. Altered handwriting
4. Hyperactivity
5. I don’t know

RTP
RESEARCH
TO PRACTICE

At this point, responses to CAR T-cell therapy in patients with MM appear very similar to those seen with CD19-directed CAR T-cell therapy for diffuse large B-cell lymphoma…

1. Agree
2. Disagree
3. I don’t know

RTP
RESEARCH
TO PRACTICE

Overview of CAR T-Cell Therapy



Modification, Courtesy, David Porter, MD

RTP RESEARCH TO PRACTICE

FDA Approves Idecabtagene Vicleucel for Multiple Myeloma

Press Release – March 26, 2021

"On March 26, 2021, the FDA approved idecabtagene vicleucel for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. This is the first FDA-approved cell-based gene therapy for multiple myeloma.

Idecabtagene vicleucel is a BCMA-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy. Each dose is customized using a patient's own T-cells, which are collected and genetically modified, and infused back into the patient.

Efficacy was evaluated in 100 patients who received idecabtagene vicleucel in the dose range of 300 to 460 x 106 CAR-positive T cells. Efficacy was established based on overall response rate (ORR), complete response (CR) rate, and duration of response (DOR), as evaluated by an Independent Response committee using the International Myeloma Working Group Uniform Response Criteria for Multiple Myeloma."

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-idecabtagene-vicleucel-multiple-myeloma

RTP RESEARCH TO PRACTICE

N Engl J Med 2021;384(8):705-16

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi, M.D., Larry D. Anderson, Jr., M.D., Ph.D., Nina Shah, M.D., Deepu Madduri, M.D., Jesús Berdeja, M.D., Sagar Lonial, M.D., Noopur Raje, M.D., Yi Lin, M.D., Ph.D., David Siegel, M.D., Ph.D., Albert Oriol, M.D., Philippe Moreau, M.D., Ibrahim Yakoub-Agha, M.D., Ph.D., Michel Delforge, M.D., Michele Cavo, M.D., Hermann Einsele, M.D., Hartmut Goldschmidt, M.D., Katja Weisel, M.D., Alessandro Rambaldi, M.D., Donna Reece, M.D., Fabio Petrocca, M.D., Monica Massaro, M.P.H., Jamie N. Connarn, Ph.D., Shari Kaiser, Ph.D., Payal Patel, Ph.D., Liping Huang, Ph.D., Timothy B. Campbell, M.D., Ph.D., Kristen Hege, M.D., and Jesús San-Miguel, M.D., Ph.D.

RTP RESEARCH TO PRACTICE

KarMMa: Tumor Response, Overall and According to Target Dose



Munshi NC et al. *N Engl J Med* 2021;384(8):705-16.

RTP RESEARCH TO PRACTICE

KarMMa: Select Adverse Events

	Any Grade	Grade 3 or 4
	no. of patients (%)	
Adverse event*		
Any	128 (100)	127 (99)
Hematologic		
Neutropenia	117 (91)	114 (89)
Anemia	89 (70)	77 (60)
Thrombocytopenia	81 (63)	67 (52)
Leukopenia	54 (42)	50 (39)
Lymphopenia	35 (27)	34 (27)
Febrile neutropenia	21 (16)	20 (16)
Cytokine release syndrome†	107 (84)	7 (5)
Neurotoxic effect‡	23 (18)	4 (3)

Munshi NC et al. *N Engl J Med* 2021;384(8):705-16.

RTP RESEARCH TO PRACTICE

CARTITUDE-1: BCMA-Directed CAR-T Study Design

CARTITUDE-1: Phase 1b/2 Study Design

Primary Objectives

- **Phase 1b:** Characterize safety and confirm phase 2 dose as informed by LEGEND-2 study
- **Phase 2:** Evaluate efficacy of JNJ-4528

Key Eligibility Criteria

- Progressive MM per IMWG criteria
- ECOG PS ≤1
- Measurable disease
- Receive ≥3 prior therapies or double refractory
- Prior PI, IMiD, anti-CD38 therapy

- Median administered dose - 0.73×10^5 ($0.52\text{-}0.89 \times 10^6$) CAR+ viable T cells/kg
- Median follow-up at data cut-off – 6 mo (3-14)



* Ciltacabtagene autoleucel

Courtesy of Edward A Stadtmauer, MD

RTP RESEARCH TO PRACTICE

EVOLVE: BCMA-Directed CAR-T Study Design

EVOLVE: Study Design



- Primary objective (phase I): safety and tolerability (DLTs, AEs) and RP2D
- Secondary objective (phase I): orva-cel pharmacokinetics, preliminary antitumor activity

Mailankody. ASCO 2020. Abstr 8504.

* Orvacabtagene autoleucel

Courtesy of Edward A Stadtmauer, MD

RTP RESEARCH TO PRACTICE

ASCO 2020: 3 BCMA CAR-T Studies

Characteristics Summary

	KarMMa: idecabtagene vicleucel (n = 128)	EVOLVE: orvacabtagene autoleucel (n = 62)	CARTITUDE-1: ciltacabtagene autoleucel (n = 29)
Age	61 (33-78)	61 (33-77)	60 (50-75)
High-risk cytogenetics, %	35	41*	27
Tumor burden in BM, %	>50% PC = 51	—	≥60% PC = 24
Extramedullary PCs, %	39	23	10
Median prior line of therapy	6 (3-16)	6 (3-18)	5 (3-18)
Triple refractory, %	84	94	86
Bridging therapy, %	88	63	79
Unique properties	Human BCMA, 4-1BB, CD3z	Modified spacer, CD4: CD8 enriched for CM	Median cell dose 0.72x106 cells/kg 2 BCMA single chain antibodies

* Included +1q21

Approved 3/26/2021

Patel K. ASCO 2020 Discussant

RTP RESEARCH TO PRACTICE

ASCO 2020: 3 BCMA CAR-T Studies

Safety

	KarMMa	EVOLVE	CARTITUDE-1
ANC ≥G3, % ⬇	89	90	100
plts ≥G3, % ⬇	52	47	69
CRS: all, ≥G3, %	84, 6	89, 3	93, 7
Med time to CRS, duration, days	1 (1-12) 5 (1-63)	2 (1-4) 4 (1-10)	7 (2-12) 4 (2-64)
ICANS: all, ≥G3, %	17, 3	13, 3	10, 3
HLH/MAS, %	—	5	? 7 (lfts)
Infections: all, ≥G3 %	69, —	40, 13	—, 19
Toci/steroid/ anakinra use, %	52/15/0	76/52/23	79/21/21

? This was not listed at MAS/HLH, I am just speculating → could this have been early MAS?

Efficacy

	KarMMa (n = 128)	EVOLVE (n = 62)	CARTITUDE-1 (n = 29)
ORR, %	73 (66-81)	92	100
sCR/CR, %	33	36	86
MRD neg ≥10^{-5}, % (of evaluable)	94	84	81
PFS, DoR, months	8.8/10.7	NR*	NR**
Screened Apheresed Treated	150 140 128	—	35 35 29

* 300 x 10^6 cell dose cohort (lowest) = PFS 9.3 months, other med F/U = 8.8 and 2.3 month

** 9 mo PFS = 86%

Patel K. ASCO 2020 Discussant

RTP RESEARCH TO PRACTICE

Bispecific Antibodies for R/R MM

Teclistamab: BCMA × CD3 DuoBody® Antibody

- Prognosis is poor for patients who progress on available classes of therapies, with ORR ~30%, mPFS of ~3 months, and mOS between 6–11 months[1]
- Teclistamab (JNJ-64007957)[a] is a humanized BCMA × CD3 bispecific IgG-4 antibody that redirects CD3+ T cells to BCMA-expressing myeloma cells
- Teclistamab induces T cell-mediated killing of myeloma cells from heavily-treated patients and in xenograft models[2-4]
- Updated results from an ongoing phase 1 study of teclistamab administered IV or SC in patients with RRMM (NCT03145181) are presented here[5]



Talquetamab: GPRC5D x CD3 Bispecific Antibody

- Talquetamab is a first-in-class DuoBody® IgG4 PAA antibody that binds to both GPRC5D and CD3
- Talquetamab redirects T cells to GPRC5D-expressing myeloma cells to mediate cell killing
- Antitumor activity was demonstrated in primary myeloma cells and xenograft models of MM[1-3]
- Talquetamab's pharmacokinetic profile presents an opportunity for less frequent SC dosing
- First-in-human phase 1 study is ongoing to evaluate talquetamab in patients with RRMM (NCT03399799)



Cevostamab: FcRH5xCD3 bispecific antibody

- Fc receptor-homolog 5 (FcRH5)
  - Expressed on myeloma cells with near 100% prevalence[1]
  - Expression on myeloma and plasma cells > normal B cells[1]
- Cevostamab
  - Humanized IgG-based T-cell-engaging bispecific antibody[1]
  - Targets FcRH5 on myeloma cells and CD3 on T cells[1]
- Ongoing Phase I dose-escalation and expansion trial (NCT03275103) is evaluating the safety and activity of cevostamab monotherapy in patients with RRMM[2]



Garfall AL et al. ASH 2020;Abstract 180;
Chari A et al. ASH 2020;Abstract 290;
Cohen AD et al. ASH 2020;Abstract 292.

RTP RESEARCH TO PRACTICE

Bispecific Antibody: Teclistamab

Teclistamab: BCMA × CD3 DuoBody® Antibody

- Prognosis is poor for patients who progress on available classes of therapies, with ORR ~30%, mPFS of ~3 months, and mOS between 6–11 months[1]
- Teclistamab (JNJ-64007957)[a] is a humanized BCMA × CD3 bispecific IgG-4 antibody that redirects $CD3^+$ T cells to BCMA-expressing myeloma cells
- Teclistamab induces T cell-mediated killing of myeloma cells from heavily-treated patients and in xenograft models[2-4]
- Updated results from an ongoing phase 1 study of teclistamab administered IV or SC in patients with RRMM (NCT03145181) are presented here[5]



Garfall AL et al. ASH 2020;Abstract 180

RTP RESEARCH TO PRACTICE

Bispecific Antibody: Talquetamab

Talquetamab: GPRC5D x CD3 Bispecific Antibody

- Talquetamab is a first-in-class DuoBody® IgG4 PAA antibody that binds to both GPRC5D and CD3
- Talquetamab redirects T cells to GPRC5D-expressing myeloma cells to mediate cell killing
- Antitumor activity was demonstrated in primary myeloma cells and xenograft models of MM[1-3]
- Talquetamab's pharmacokinetic profile presents an opportunity for less frequent SC dosing
- First-in-human phase 1 study is ongoing to evaluate talquetamab in patients with RRMM (NCT03399799)



Chari A et al. ASH 2020;Abstract 290;

Bispecific Antibody: Cevostamab

Cevostamab: FcRH5xCD3 bispecific antibody

- Fc receptor-homolog 5 (FcRH5)
  - Expressed on myeloma cells with near 100% prevalence[1]
  - Expression on myeloma and plasma cells > normal B cells[1]
- Cevostamab
  - Humanized IgG-based T-cell-engaging bispecific antibody[1]
  - Targets FcRH5 on myeloma cells and CD3 on T cells[1]
- Ongoing Phase I dose-escalation and expansion trial (NCT03275103) is evaluating the safety and activity of cevostamab monotherapy in patients with RRMM[2]



Cohen AD et al. ASH 2020;Abstract 292.

RTP RESEARCH TO PRACTICE

Dr Richards: Reflections on being an oncology nurse practitioner

RTP
RESEARCH
TO PRACTICE

13th Annual Oncology Grand Rounds

A Complimentary NCPD Live Webinar Series
Held During the 46th Annual ONS Congress

Gynecologic Cancers

Tuesday, April 27, 2021
5:00 PM – 6:30 PM ET

Medical Oncologists

Robert L Coleman, MD
Thomas J Herzog, MD
Krishnansu S Tewari, MD

Oncology Nurse Practitioners

Paula J Anastasia, MN, RN, AOCN
Courtney Arn, CNP
Kimberly A Spickes, MNSc, RN, APRN, OCN, ACNP-BC

Moderator

Neil Love, MD

RTP RESEARCH TO PRACTICE


Charise Gleason, MSN, NP-C, AOCNP


Patricia Mangan, RN MSN CRNP APN, BC


Tiffany A Richards, PhD, ANP-BC, AOCNP

Thank you for joining us!

NCPD credit information will be emailed to each participant shortly.

RTP
RESEARCH
TO PRACTICE